by HARIZAH KAMEL / graphic by MZUKRI
SOLUTION Group Bhd’s unit Solution Biologics Sdn Bhd has signed a registration, manufacturing and commercialisation agreement with CanSino Biologics Inc, sealing its presence in the race for the Covid-19 vaccine.
The agreement will allow Solution Biologics to commence marketing and distribution of the vaccine developed by CanSino in Malaysia.
Solution Group stated in a Bursa Malaysia filing yesterday that Solution Biologics would register with Malaysia’s National Pharmaceutical Regulatory Agency to apply for the market authorisation certificate.
The company will establish a state-of-the-art fill and finish facility to host a technology transfer for the filling, finishing and final quality control of CanSino’s recombinant Covid-19 vaccine.
The facility will be established at Solution Biologics’ current premises located at Technology Park Malaysia in Bukit Jalil, Kuala Lumpur.
CanSino is a biotech company in China, dedicated to developing novel vaccines and therapeutics for unmet medical needs. Currently, it is developing a novel recombinant Ad5-nCoV vaccine composed of an adenovirus type 5 vector (liquid for injection).
The company will collaborate with Solution Biologics in obtaining the necessary approvals for the registration and commercialisation of the product in Malaysia.
“Upon the product’s registration, CanSino will be partnering with Solution Biologics in the supplying of bulk product for further manufacturing (fill and finish) of the finished product, its final quality control release and its commercialisation by Solution Biologics in Malaysia,” Solution Group said.
The parties agreed to combine efforts in co-development of the product including, in particular, the performance of the studies, registration and commercialisation in Malaysia, and manufacturing and supply of the bulk product for the manufacturing of the finished product for Malaysia.
The group also said upon the successful implementation of the terms, interests and the intention of the parties as set out in the agreement, it expects the collaboration to contribute positively to its earnings in the future.
Solution Biologics is among the list of companies in the market involved in procuring a vaccine for the virus pandemic.
Earlier this week, Bintai Kinden Corp Bhd and Kanger International Bhd respectively entered into separate agreements entailing Covid-19 vaccines.
Bintai Kinden inked a licensing agreement with US-based Generex Biotechnology Corp and its wholly-owned subsidiary, NuGenerex Immuno-Oncology, concerning licensed compounds and research information in the synthetic peptide vaccine for SARS-CoV-2 against Covid-19.
The company said it would be granted the exclusive licence in Malaysia and related territories for commercialisation and development of compounds and research information of the vaccine.
Additionally, it will have the first right of refusal in the development and commercialisation of vaccine compounds and research information in New Zealand, Australia and global halal markets.
Meanwhile, Kanger International entered into a proxy agreement with China’s Shenzhen Public Health Technology Co Ltd for the latter to procure dealership/distributorship from China National Biotec Group Company Ltd, the subsidiary of China National Pharmaceutical Group Corp.
Ho Wah Genting Bhd’s unit HWGB Biotech Sdn Bhd also signed an agreement with US-based E-Mo Biology Inc to invest in Phase IV clinical trials for a new indication, which proposes the use of existing poliomyelitis virus vaccines for Covid-19.
Meanwhile, Pharmaniaga Bhd said in a bourse filing last month that it offered its existing suitable facility to be repurposed to undertake the vaccine fill and finish.
It clarified that following the announcement made by the minister of science, technology and innovation that the government could use the facilities of Pharmaniaga and Duopharma Biotech Bhd for fill and finish of a potential Covid-19 vaccine, as at to date, the company has yet to enter into an agreement with the government for the project.